Intraocular inflammation after intravitreal injections. Part 2: "What to do?"

Intravitreal drug injections are one of the most common procedures in daily ophthalmic practice. With the increase in the number of manipulations, the expansion of indications for them, as well as the registration of new drugs, the problem of inflammatory adverse events, including sterile intraocular inflammation, brolucizumab-associated retinovasculitis, and post-injection infectious endophthalmitis, becomes more and more urgent. Their timely diagnosis and treatment is impossible without knowledge of the clinical manifestations and existing therapeutic options. This review provides a brief description of current approaches to the prevention, differential diagnosis and treatment of various forms of inflammatory adverse events associated with intravitreal drug administration. The emphasis is on recommendations developed by Russian specialists.